Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

43.30 -0.91 (-2.05%)
Streaming Delayed Price Updated: 9:30 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added. 
Via Benzinga
News headline image
Royalty Pharma Announces Expansion of Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces R&D Funding Collaboration With Merck
Novel collaboration structure supports pipeline innovation 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings ↗
 
Via Benzinga
News headline image
Expert Ratings for Royalty Pharma ↗
  Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Royalty Pharma: Q2 Earnings Insights ↗
  Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Expert Ratings for Royalty Pharma ↗
Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Royalty Pharma's Return On Capital Employed Insights ↗
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters. 
Via Benzinga
News headline image
Warren Buffett's Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals ↗
Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing. 
Via Benzinga
News headline image
Jim Cramer Shares His Takes On First Solar, Royalty Pharma And More ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royalty Pharma PLC (NASDAQ: RPRX) is going higher. "Hold on to it." 
Via Benzinga
News headline image
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Executives Sell Around $325M Of 3 Stocks ↗
Gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Expert Ratings for Royalty Pharma ↗
Analysts have provided the following ratings for Royalty Pharma (NASDAQ:RPRX) within the last quarter: 
Via Benzinga
News headline image
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests ↗
 
Via Benzinga
News headline image
Warren Buffett Stocks: Royalty Pharma plc ↗
As of March 31st, 2022, Buffett’s Berkshire Hathaway owned about 1.5 million shares of Royalty Pharma plc for a market value of $58.3 million. Let's analyze the healthcare company in greater detail. 
Via Talk Markets
News headline image
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation' ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Royalty Pharma: Q1 Earnings Insights ↗
Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap: Royalty Pharma Q1 Earnings ↗
Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Management of Technology Companies Continue Selling - Zillow (Z) ↗
In a week where we saw most market indices rebound sharply, insiders scaled back their buying after three weeks of elevated buying. Buying declined by 64% in absolute dollar terms and 26% in terms of... 
Via Benzinga
News headline image
Royalty Pharma Earnings Perspective: Return On Capital Employed ↗
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters. 
Via Benzinga
News headline image
Warren Buffett Stocks: Berkshire Hathaway Goes On Offense In Stock Market, Adds More Apple ↗
Buffett's Berkshire added to Apple and Chevron during the Q1 sell-off. More details to come. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022 ↗
Upgrades 
Via Benzinga
News headline image
How To Attend Royalty Pharma Q1 2022 Earnings Conference Call ↗
Royalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Royalty Pharma (RPRX) Conference Call Follow this link to... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Expedia And 3 Other Stocks Insiders Are Selling ↗
Although gold futures traded lower on Thursday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or... 
Via Benzinga
News headline image
Hopeful Golden Cross Forms On Royalty Pharma's Chart ↗
If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called "golden cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
News headline image
Looking Into Royalty Pharma's Return On Capital Employed ↗
According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67%... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.